Literature DB >> 21471242

Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Ema T Crooks1, Tommy Tong, Keiko Osawa, James M Binley.   

Abstract

HIV-1 viruses and virus-like particles (VLPs) bear nonnative "junk" forms of envelope (Env) glycoprotein that may undermine the development of antibody responses against functional gp120/gp41 trimers, thereby blunting the ability of particles to elicit neutralizing antibodies. Here, we sought to better understand the nature of junk Env with a view to devising strategies for its removal. Initial studies revealed that native trimers were surprisingly stable in the face of harsh conditions, suggesting that junk Env is unlikely to arise by trimer dissociation or gp120 shedding. Furthermore, the limited gp120 shedding that occurs immediately after synthesis of primary HIV-1 isolate Envs is not caused by aberrant cleavage at the tandem gp120/gp41 cleavage sites, which were found to cleave in a codependent manner. A major VLP contaminant was found to consist of an early, monomeric form of gp160 that is glycosylated in the endoplasmic reticulum (gp160ER) and then bypasses protein maturation and traffics directly into particles. gp160ER was found to bind two copies of monoclonal antibody (MAb) 2G12, consistent with its exclusively high-mannose glycan profile. These findings prompted us to evaluate enzyme digests as a way to remove aberrant Env. Remarkably, sequential glycosidase-protease digests led to a complete or near-complete removal of junk Env from many viral strains, leaving trimers and viral infectivity largely intact. "Trimer VLPs" may be useful neutralizing antibody immunogens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471242      PMCID: PMC3126298          DOI: 10.1128/JVI.00154-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Authors:  Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

2.  Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.

Authors:  R L Dewar; M B Vasudevachari; V Natarajan; N P Salzman
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.

Authors:  E Fenouillet; R Miquelis; R Drillien
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

5.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Authors:  Rob J Center; Richard D Leapman; Jacob Lebowitz; Larry O Arthur; Patricia L Earl; Bernard Moss
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  P L Earl; R W Doms; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more
  72 in total

1.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

Review 3.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

4.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

5.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

6.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

7.  Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41.

Authors:  Barbara Diaz-Aguilar; Karen Dewispelaere; Hyun Ah Yi; Amy Jacobs
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

8.  The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.

Authors:  Matthew P Wood; Amy L Cole; Colleen R Eade; Li-Mei Chen; Karl X Chai; Alexander M Cole
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

9.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.